U.S. stock night market fluctuations: Purple Biotech rose 7.35% in night trading, with clear capital flow. Can market sentiment be sustained?

U.S. Stock Night Market Movements Purple Biotech rose 7.35% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Eli Lilly rose 0.04% in the night market. Based on recent key news: On February 20, Eli Lilly announced that its drug Omvoh achieved three years of hormone-free remission in patients with Crohn's disease. This news boosted market confidence in its drug pipeline, driving the stock price up. Source: PR Newswire On February 20, Benzinga Edge's ranking showed that Eli Lilly had a high momentum score in the market, indicating that its stock outperformed the market. This strong performance attracted investor attention. Source: Benzinga On February 20, Bridgewater Associates increased its holdings in Eli Lilly, showing institutional investors' confidence in the company. This move further supported the stock price increase. Source: MarketBeat The pharmaceutical industry is turbulent, and policy risks should be monitored. Novo Nordisk fell 0.06% in the night market. Based on recent key news: On February 20, Novo Nordisk announced the nomination of Jan van de Winkel and Ramona Sequeira to the board, marking the first personnel adjustment since last year's restructuring. This move may affect the company's governance structure, attracting market attention. On February 20, Novo Nordisk filed a patent infringement lawsuit against Hims & Hers Health regarding its injectable weight loss drug, raising market concerns about the potential impact of legal disputes on the company's business. On February 19, competition between Hims & Hers Health and Novo Nordisk in the GLP-1 drug market intensified, putting pressure on Novo Nordisk's stock price. Denmark's slow economic growth significantly impacts pharmaceutical companies. Pfizer rose 0.38% in the night market. Based on recent key news: On February 20, Barclays analyst Emily Field assigned an underweight rating to Pfizer stock and set a target price of $25. This move may lead to a decline in investor confidence in Pfizer stock, affecting the stock price. On February 20, BioNTech sued Moderna in federal court in Delaware, alleging that its COVID-19 vaccine mNEXSPIKE infringed on BioNTech and Pfizer's patents. This lawsuit may impact Pfizer's market performance. On February 21, Pfizer's efforts to catch up in the GLP-1 drug field attracted attention. Although Pfizer has a long history of success in drug development, the market remains cautious about whether it can achieve breakthroughs in this area. The pharmaceutical industry faces patent litigation risks